The ongoing CompassHER2-pCR trial will enroll 1250 patients with stage II-IIIA HER2+ breast cancer and determine recurrence-free survival with a treatment approach nearly identical to the DAPHNe trial. This evidence concerns the gene ERBB2 and breast carcinoma.